Hematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell Anemia
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
The globally widespread single-gene disorders β-thalassemia and sickle cell anemia (SCA) can only be cured by allogeneic hematopoietic stem cell transplantation (HSCT). HSCT treatment of thalassemia has substantially improved over the last two decades, with advancements in preventive strategies, control of transplant-related complications, and preparative regimens. A risk class-based transplantation approach results in disease-free survival probabilities of 90%, 84%, and 78% for class 1, 2, and 3 thalassemia patients, respectively. Because of disease advancement, adult thalassemia patients have a higher risk for transplant-related toxicity and a 65% cure rate. Patients without matched donors could benefit from haploidentical mother-to-child transplantation. There is a high cure rate for children with SCA who receive HSCT following myeloablative conditioning protocols. Novel non-myeloablative transplantation protocols could make HSCT available to adult SCA patients who were previously excluded from allogeneic stem cell transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Bone Marrow Transplantation in Patients with Thalassemia
Lucarelli, G., Galimberti, M., Polchi, P., Angelucci, E., Baronciani, D., Giardini, C., Politi, P., Durazzi, S. M. T., Muretto, P., & Albertini, F. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220701 · Cited by 636 · cited 1×
“The influence of pretransplant characteristics on the outcome of transplantation was analyzed in 161 patients ,17 yr of age, who were all treated with exactly the same regimen (Storb et al. 1977; Lucarelli et al. 1990).”
MethodSelf-citationLong-term results of related myeloablative stem-cell transplantation to cure sickle cell disease
Bernaudin, F., Socie, G., Kuentz, M., Chevret, S., Duval, M., Bertrand, Y., Vannier, J.-P., Yakouben, K., Thuret, I., Bordigoni, P., et al. (2007) · Blood · doi:10.1182/blood-2007-03-079665 · Cited by 515
Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease
Hsieh, M. M., Kang, E. M., Fitzhugh, C. D., Link, M. B., Bolan, C. D., Kurlander, R., Childs, R. W., Rodgers, G. P., Powell, J. D., & Tisdale, J. F. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904971 · Cited by 455
World Distribution, Population Genetics, and Health Burden of the Hemoglobinopathies
Williams, T. N., & Weatherall, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011692 · Cited by 430
Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease
Locatelli, F. (2003) · Blood · doi:10.1182/blood-2002-07-2090 · Cited by 386 · cited 1×
“…88% Class 3: 87% Adult: 66% Class 1–2: 85% Class 3: 82% Adult: 62% Lucarelli et al. 2008 68 MUD 79.3% 40% La Nasa et al. 2005a 33 Cord blood 100% 79% Locatelli et al. 2003 70 MSD/MRD 83% 73% Ghavamzadeh et al. 1997 49 Related: 28 Unrelated: 21 89% (all patients) Related: 82% Unrelated: 71%…”
InfluentialWalters, M. C., Storb, R. F., Patience, M., Leisenring, W. M., Taylor, T., Sanders, J. E., Buchanan, G. E., Rogers, Z. R., Dinndorf, P. A., Davies, S. C., et al. (2000) · PubMed · doi:10.1182/blood.v95.6.1918 · Cited by 361
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia
Walters, M. C., Patience, M., Leisenring, W., Rogers, Z. R., Aquino, V. M., Buchanan, G. R., Roberts, I. A. G., Yeager, A. M., Hsu, L., Adamkiewicz, T., et al. (2001) · Biology of Blood and Marrow Transplantation · doi:10.1053/bbmt.2001.v7.pm11787529 · Cited by 324 · cited 1×
“Walters et al. (2001) observed stable MC in 13 out of 50 patients (26”
BackgroundIannone, R., Casella, J. F., Fuchs, E. J., Chen, A. R., Jones, R. J., Woolfrey, A., Amylon, M., Sullivan, K. M., Storb, R. F., & Walters, M. C. (2003) · Biology of Blood and Marrow Transplantation · doi:10.1016/s1083-8791(03)00192-7 · Cited by 269 · cited 1×
“In a retrospective multicenter series, Iannone et al. (2003) described a non-myeloablative HSCT approach in six pediatric patients with SCD and one with thalassemia.”
BackgroundVermylen, C., Cornu, G., Ferster, A., Brichard, B., Ninane, J., Ferrant, A., Zenebergh, A., Maes, P., Dhooge, C., Benoit, Y., et al. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701291 · Cited by 260 · cited 1×
“The results of transplantation might be even better if HSCT were performed in children before the development of irreversible sickle vasculopathy-related complications (Vermylen et al. 1998; Lucarelli et al. 2011).”
BackgroundAPLASTIC ANAEMIA TREATED BY MARROW TRANSPLANTATION
Donnall Thomas, E., Storb, R., Fefer, A., Slichter, S., Bryant, J., Dean Buckner, C., Neiman, P., Clift, R., Funk, D., & Lerner, K. (1972) · The Lancet · doi:10.1016/s0140-6736(72)90292-9 · Cited by 250 · cited 1×
“Cyclophosphamide (CY) is a well-established agent for providing adequate immunosuppression for allogeneic engraftment (Thomas et al. 1972; Storb et al. 1991).”
Background
Cited by
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Snowden, J. A., Sánchez-Ortega, I., Corbacioglu, S., Basak, G. W., Chabannon, C., de la Camara, R., Dolstra, H., Duarte, R. F., Glass, B., Greco, R., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01691-w · Cited by 379
Sureda, A., Bader, P., Cesaro, S., Dreger, P., Duarte, R. F., Dufour, C., Falkenburg, J. H. F., Farge-Bancel, D., Gennery, A., Kröger, N., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.6 · Cited by 337
for the European Society for Blood and Marrow Transplantation (EBMT), Duarte, R. F., Labopin, M., Bader, P., Basak, G. W., Bonini, C., Chabannon, C., Corbacioglu, S., Dreger, P., Dufour, C., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0516-2 · Cited by 337
A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia.
Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., Voskaridou, E., Liew, H.-K., Pazgal-Kobrowski, I., Forni, G. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910182 · Cited by 332
Hematopoietic Stem Cells and Their Roles in Tissue Regeneration
Lee, J. Y., & Hong, S.-H. (2020) · International Journal of Stem Cells · doi:10.15283/ijsc19127 · Cited by 165
“last two decades, and 80% disease-free survival has been reported with allogeneic HSCT (30).”
BackgroundGene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β A(T87Q) - Globin Gene
Negre, O., Eggimann, A.-V., Beuzard, Y., Ribeil, J.-A., Bourget, P., Borwornpinyo, S., Hongeng, S., Hacein-Bey, S., Cavazzana, M., Leboulch, P., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.007 · Cited by 159
“Disease-free survival after AHSCT is approximately 88% in pediatric subjects(12) and 65% in adults.(13) Recent transplantation trials conducted during the last 15 years for young SCD patients reported a disease free-survival rate of 85–90%.”
BackgroundBetts, M. B., Flight, P. A., Paramore, L. C., Li, T., Milenković, D., & Sheth, S. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.12.003 · Cited by 118
Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation
Motta, I., Bou‐Fakhredin, R., Taher, A. T., & Cappellini, M. D. (2020) · Drugs · doi:10.1007/s40265-020-01341-9 · Cited by 125
Zhou, X. ‐., Zhu, F., Li, J., Mao, W., Zhang, D.-M., Liu, M.-L., Hei, A., Dai, D., Jiang, P., Shan, X., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139485 · Cited by 101
Pathophysiology and treatment of patients with beta-thalassemia – an update
Fibach, E., & Rachmilewitz, E. A. (2017) · F1000Research · doi:10.12688/f1000research.12688.1 · Cited by 108
“…HSCT (allo-HSCT) is currently the only definitive cure for transfusion-dependent young patients before the development of IO-related tissue damage 97 . β -thal major patients with good risk features have a >90% chance of a successful outcome 98,99 , but allo-HSCT in high-risk patients is…”
BackgroundBoulad, F., Wang, X., Qu, J., Taylor, C., Ferro, L., Karponi, G., Bartido, S., Giardina, P., Heller, G., Prockop, S. E., et al. (2014) · Blood · doi:10.1182/blood-2013-06-507178 · Cited by 64
“The only curative treatment is allogeneic bone marrow transplantation from a matched, related donor.(4,5) Most patients, however, lack such matched donor.”
BackgroundCustomizing the genome as therapy for the β-hemoglobinopathies.
Canver, M. C., & Orkin, S. H. (2016) · Blood · doi:10.1182/blood-2016-01-678128 · Cited by 61
Chen, N., Wang, W., Wang, F., Dong, L., Zhao, S., Zhang, W., He, J., Huang, H., & Zhu, F. (2018) · International Journal of Immunogenetics · doi:10.1111/iji.12411 · Cited by 58
2017 Clinical trials update in new treatments of β‐thalassemia
Makis, A., Hatzimichael, E., Papassotiriou, I., & Voskaridou, E. (2016) · American Journal of Hematology · doi:10.1002/ajh.24530 · Cited by 59
“Allo-HSCT in high risk patients is challenging due to high rates of graft rejection and transplant-related mortality [14].”
BackgroundBoulad, F., Maggio, A., Wang, X., Moi, P., Acuto, S., Kogel, F., Takpradit, C., Prockop, S. E., Mansilla‐Soto, J., Cabriolu, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01554-9 · Cited by 69
Karponi, G., Psatha, N., Lederer, C. W., Adair, J. E., Zervou, F., Ζώγας, Ν., Kleanthous, M., Tsatalas, C., Anagnostopoulos, Α., Sadelain, M., et al. (2015) · Blood · doi:10.1182/blood-2015-03-629618 · Cited by 56
“Allogeneic hematopoietic stem cell transplantation (allo-HSCT), although curative, is limited by the lack of matched donor availability.(2,3) Thus, most patients undergo palliative, lifelong transfusions andchelation(1) that compromisequality andduration of life.”
BackgroundKahraman, S., Beyazyurek, C., Yeşilipek, A., Öztürk, G., Ertem, M., Anak, S. S., Kansoy, S., Aksoylar, S., Kuşkonmaz, B., Öniz, H., et al. (2014) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2014.05.010 · Cited by 53
Iron dysregulation in beta-thalassemia
Leecharoenkiat, K., Lithanatudom, P., Sornjai, W., & Smith, D. R. (2016) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2016.07.035 · Cited by 59
“…beta-thalassemia can be achieved by allogeneic hematopoietic stem cell transplantation, but the need to control transplant-related complications and the requirement for matched donors make this option available to only some patients [99] , and as many as 60% of patients lack a suitable donor [99] .”
BackgroundGaziev, J., Marziali, M., Isgrò, A., Sodani, P., Paciaroni, K., Gallucci, C., Andreani, M., Testi, M., Angelis, G. D., Alfieri, C., et al. (2013) · Blood · doi:10.1182/blood-2013-07-513473 · Cited by 50
“75 Median CD34(1) cells, 3 10(6)/kg 4 (1-13) 6.”
Self-citationPeranteau, W. H., Hayashi, S., Abdulmalik, O. Y., Chen, Q., Merchant, A. M., Asakura, T., & Flake, A. W. (2015) · Blood · doi:10.1182/blood-2015-03-636803 · Cited by 50
“Additional studies in hemoglobinopathies demonstrating decreased apoptosis of normal donor erythroid progenitors, longer normalRBC survival, and similar findings of higher donor erythroid engraftment following mixed chimerism in patients with Thal and SCD also support this hypothesis.(3,20,46-49) These results are enc…”
BackgroundResultInfluentialCruz, L. J., van Dijk, T., Vepris, O., Li, T. M. W. Y., Schomann, T., Baldazzi, F., Kurita, R., Nakamura, Y., Grosveld, F. G., Philipsen, S., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120580 · Cited by 53
“The only permanent cure is transplantation of healthy hematopoietic stem cells (HSCs) [4,5], but the treatment is risky and there is a shortage of suitable donors.”
BackgroundMixed chimerism in haemoglobinopathies: from risk of graft rejection to immune tolerance
Andreani, M., Testi, M., & Lucarelli, G. T. (2014) · Tissue Antigens · doi:10.1111/tan.12313 · Cited by 48
Self-citationAnsari, M., Huezo-Diaz, P., Rezgui, M. A., Marktel, S., Duval, M., Bittencourt, H. N. D. S., Cappelli, B., & Krajinović, M. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.321 · Cited by 47
Goodman, M., & Malik, P. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716653729 · Cited by 52
Thalassemia: A Review of the Challenges to the Families and Caregivers
Yousuf, R., Akter, S., Wasek, S. M., Sinha, S., Ahmad, R., & Haque, M. (2022) · Cureus · doi:10.7759/cureus.32491 · Cited by 43
“Image Credit: Susmita Sinha Hematopoietic stem cell transplantation and gene therapy Multiple studies reported that single-gene disorders β-thalassemia and sickle cell anemia (SCA) have the possibility to be cured through allogeneic hematopoietic stem cell transplantation (HSCT) [46-48].”
BackgroundInfluentialTransplantation tolerance: from theory to clinic
Fuchs, E. J. (2014) · Immunological Reviews · doi:10.1111/imr.12154 · Cited by 48
“Getting donor cells to engraft is a much greater challenge in patients with SCD compared with patients with cancer, because the vast majority of SCD patients have been sensitized to HLA alloantigens by transfusion and, unlike cancer patients, their immune systems have not been suppressed by cytotoxic chemotherapy and…”
BackgroundInfluentialManagement of the ThalassemiasPreprint
Olivieri, N. F., & Brittenham, G. M. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011767 · Cited by 40
Hematopoietic SCT for the Black African and non-Black African variants of sickle cell anemia
Lucarelli, G. T., Isgrò, A., Sodani, P., Marziali, M., Gaziev, J., Paciaroni, K., Gallucci, C., Cardarelli, L., Ribersani, M., Alfieri, C., et al. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.167 · Cited by 38
Self-citationNovel Therapeutic Advances in β-Thalassemia
Makis, A. C., Voskaridou, E., Papassotiriou, I., & Hatzimichael, E. C. (2021) · Biology · doi:10.3390/biology10060546 · Cited by 43
“AlloHSCT in thalassemic patients with high-risk criteria poses difficulties due to elevated rates of graft rejection and transplant-related mortality [16].”
BackgroundRevolutionising healing: Gene Editing's breakthrough against sickle cell disease
Dimitrievska, M., Bansal, D., Vitale, M., Strouboulis, J., Miccio, A., Nicolaides, K. H., Hoss, S. E., Shangaris, P., & Jackow, J. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101185 · Cited by 46
Soni, S. (2020) · American Journal of Hematology · doi:10.1002/ajh.25909 · Cited by 42
“Disease-free survival exceeds 85%, depending on patients' age, HLA-matching and clinical factors like iron overload and hepatomegaly.(12,13) Fully matched sibling donor transplant in younger patients is considered the standard of care, while alternative donor HSCT (unrelated or haploidentical donors) is still experime…”
BackgroundAnurathapan, U., Pakakasama, S., Rujkijyanont, P., Sirachainan, N., Songdej, D., Chuansumrit, A., Sirireung, S., Charoenkwan, P., Jetsrisuparb, A., Issaragrisil, S., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.04.023 · Cited by 37
“Pretransplantation therapies include administration of hydroxyurea and azathioprine to eradicate marrow and hypertransfusion and aggressive chelation to suppress endogenous erythropoiesis [12,13].”
BackgroundGene therapy for genetic diseases: challenges and future directions
Beibei, Q. I. E., Tuo, J., Chen, F., Ding, H., & Lyu, L. (2025) · MedComm · doi:10.1002/mco2.70091 · Cited by 45
Lüftinger, R., Zubarovskaya, N., Galimard, J., Cseh, A., Salzer, E., Locatelli, F., Algeri, M., Yeşilipek, A., de la Fuente, J., Isgrò, A., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-021-04732-4 · Cited by 35
Delgouffe, E., Braye, A., & Goossens, E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.854186 · Cited by 38
“Beta-thalassemia is an autosomal recessive disease in which the production of beta-globin chains, that constitute adult hemoglobin, is disturbed (121).”
BackgroundInvestigational drugs in phase I and phase II clinical trials for thalassemia
Motta, I., Scaramellini, N., & Cappellini, M. D. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1335709 · Cited by 27
“However, the treatment itself carries the risk of graft-versus-host disease (GVHD) [16,17].”
BackgroundGene modification therapies for hereditary diseases in the fetus
Mattar, C. N. Z., Chan, J. K. Y., & Choolani, M. A. (2023) · Prenatal Diagnosis · doi:10.1002/pd.6347 · Cited by 28
“Children with pre‐ transplantation risk factors have a lower survival rate (60%), higher graft‐vs‐host disease (5%–8%), and graft rejection (~30%–40% of recipients with mixed chimerism), following HSCT.10,76,77 The 25%– 30% of patients who do not have a suitable donor require lifelong blood transfusions iron chelation…”
BackgroundCURING HEMOGLOBINOPATHIES: CHALLENGES AND ADVANCES OF CONVENTIONAL AND NEW GENE THERAPY APPROACHES.
Motta, I., Ghiaccio, V., Cosentino, A., & Breda, L. (2019) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2019.067 · Cited by 26
“transplant-related mortality (TRM) positively increased between classes 1, 2, and 3.(9)”
BackgroundHematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review
Rostami, T., Rad, S., Rostami, M. R., Mirhoseini, S. A., Alemi, H., Khavandgar, N., Janbabai, G., Kiumarsi, A., Kasaeian, A., & Mousavi, S. A. (2024) · Cell Transplantation · doi:10.1177/09636897241246351 · Cited by 25
“HSCT is currently a curative treatment for severe SCD 7–10 .”
Satirapod, C., Sukprasert, M., Panthan, B., Charoenyingwattana, A., Chitayanan, P., Chantratita, W., Choktanasiri, W., Trachoo, O., & Hongeng, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225457 · Cited by 26
“However, SCT is only possible for a minority of patients with a suitable human leukocyte antigen (HLA)-matched donor and who can afford the costly treatment [11, 12].”
BackgroundAllogeneic/Matched Related Transplantation for β-Thalassemia and Sickle Cell Anemia
Bernaudin, F., Pondarré, C., Galambrun, C., & Thuret, I. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-1-4939-7299-9_4 · Cited by 29
Luspatercept for β-thalassemia: beyond red blood cell transfusions
Taher, A. T., & Cappellini, M. D. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1968825 · Cited by 19
“Additionally, patients may be at risk of graft-versushost disease and rejection [35,37,38].”
BackgroundSaad, H. K. M., Rahman, A. A. A., Ghani, A. S. A., Taib, W. R. W., Ismail, I., Johan, M. F., Al-wajeeh, A. S., & Al‐Jamal, H. A. N. (2022) · Biomedicines · doi:10.3390/biomedicines10010189 · Cited by 29
Kansal, A. R., Reifsnider, O. S., Brand, S. B., Hawkins, N., Coughlan, A., Li, S., Cragin, L. S., Paramore, C., Dietz, A. C., & Caro, J. J. (2021) · Journal of Market Access & Health Policy · doi:10.1080/20016689.2021.1922028 · Cited by 19
Hematopoietic stem cell transplantation for people with ß-thalassaemia major
Jagannath, V. A., Fedorowicz, Z., Hajeri, A. A., & Sharma, A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008708.pub4 · Cited by 24
Health state utilities associated with treatment for transfusion-dependent β-thalassemia
Matza, L. S., Paramore, L. C., Stewart, K. D., Karn, H., Jobanputra, M., & Dietz, A. C. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-019-01136-0 · Cited by 18
“The literature search focused on patient experiences with TDT [39–41], transfusions [25, 42, 43], iron chelation [21, 23, 24], allo-HSCT [9, 12, 44, 45], gene therapy [13], and GvHD [45, 46].”
BackgroundRiley, J. S., McClain, L. E., Stratigis, J. D., Coons, B. E., Ahn, N. J., Li, H., Loukogeorgakis, S. P., Fachin, C. G., Dias, A. I. B. S., Flake, A. W., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001208 · Cited by 17
Analysis of circRNAs and circRNA-associated competing endogenous RNA networks in β-thalassemia
Fang, Y., Ruan, H., Li, S., Hou, W., Qiu, Y., Deng, L., Su, S., Chen, P., Pang, L., & Lai, K. (2022) · Scientific Reports · doi:10.1038/s41598-022-12002-0 · Cited by 19
Andreani, M., Gianolini, M. E., Testi, M., Battarra, M., Galluccio, T., Morrone, A., Sodani, P., Lucarelli, G., Roncarolo, M., & Gregori, S. (2014) · Chimerism · doi:10.1080/19381956.2015.1103423 · Cited by 16
Self-citationNovel therapies in β‐thalassaemia
Grech, L., Borg, K., & Borg, J. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14918 · Cited by 19
“For this procedure, ideally the donor is a human leukocyte antigen-identical sibling of the patient, but since >60% of patients lack such a suitable family donor, transplants from matched unrelated donors are still possible.(22) The outcomes of HSCT in β-thalassaemia patients depends on several factors, such as iron o…”
BackgroundXu, Y., Chen, S., Yin, X., Shen, X., Pan, X., Chen, F., Jiang, H., Liang, Y., Wang, W., Xu, X., et al. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.228569 · Cited by 16
Privileged substructures for anti-sickling activity via cheminformatic analysis
Phanus‐umporn, C., Shoombuatong, W., Prachayasittikul, V., Anuwongcharoen, N., & Nantasenamat, C. (2018) · RSC Advances · doi:10.1039/c7ra12079f · Cited by 21
Cortabarría, A. S. D. V., Makhoul, L., Strouboulis, J., Lombardi, G., Oteng‐Ntim, E., & Shangaris, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.624477 · Cited by 15
“There is a theoretical advantage provided by heterozygous SCD inheritance, as carriers of SCD are 90% less likely to suffer from severe malaria (Allison, 1954; Weatherall, 2011; Luzzatto, 2012).”
BackgroundImmunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD)
Mhandire, K., Saggu, K., & Buxbaum, N. P. (2021) · Metabolites · doi:10.3390/metabo11110736 · Cited by 16
Gamage, U., Warnakulasuriya, K., Hansika, S., & Silva, G. N. (2023) · Thalassemia Reports · doi:10.3390/thalassrep13010006 · Cited by 20
“In HSCT, allogenic stem cells are used as vectors to correct the genetic defects in β-thalassemia by introducing the essential wild-type HBB for normal hematopoiesis [31].”
BackgroundAlternative donor transplant of benign primary hematologic disorders
Tolar, J., Sodani, P., & Symons, H. J. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.1 · Cited by 15
Self-citationMaximizing longevity: erythropoietin’s impact on sickle cell anaemia survival rates
Obeagu, E. I. (2024) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000001763 · Cited by 14
“Patients with SCA already face an elevated risk of thromboembolic complications, making the decision to use EPO therapy complex [37,38] .”
BackgroundGhazaly, E. A., Sajic, M., Rantell, K. R., McBlane, J. W., Johnston, J. D., Niewiarowska, A., Butler, A. S., & Cole, S. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46080485 · Cited by 24
“At present, the only cure for SCD and TDT is a stem cell or bone marrow transplant; however, occurrences of this are limited due to the risks associated with rejection and graft-versus-host disease (GvHD) [18,20].”
BackgroundHematopoietic stem cell transplantation for people with β-thalassaemia
Sharma, A., Jagannath, V. A., & Puri, L. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008708.pub5 · Cited by 23
“Those without matched family or unrelated donors could benefit from haploidentical transplantation (Isgro 2010; Lucarelli 2012; Angelucci 2014; Baronciani 2016).”
BackgroundHaematopoietic stem cell transplantation in Nigerian sickle cell anaemia children patients
Isgrò, A., Paciaroni, K., Gaziev, J., Sodani, P., Gallucci, C., Marziali, M., Angelis, G. D., Alfieri, C., Ribersani, M., Roveda, A., et al. (2015) · Nigerian Medical Journal · doi:10.4103/0300-1652.160355 · Cited by 14
“Recurrent priapism 1 Median donor age, years 11 (1-26) Median Hb, gr/dl 7.”
BackgroundSelf-citationKharya, G., Bakane, A., & Rauthan, A. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.28909 · Cited by 14
Zaidman, I., Rowe, J. M., Khalil, A., Arush, M. W. B., & Elhasid, R. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.03.003 · Cited by 14
“[4], is now applied worldwide and remains the only proven curative option for patients with hemoglobinopathies, both thalassemia and SCA [1,4-11].”
BackgroundInfluentialRiley, J. S., McClain, L. E., Stratigis, J. D., Coons, B. E., Li, H., Hartman, H. A., & Peranteau, W. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1800183 · Cited by 12
Clinical Management of Patients With Thalassemia Syndromes
Martin, M., & Haines, D. (2016) · Clinical journal of oncology nursing · doi:10.1188/16.cjon.310-317 · Cited by 12
FV Vectors as Alternative Gene Vehicles for Gene Transfer in HSCs
Simantirakis, E., Tsironis, I., & Vassilopoulos, G. (2020) · Viruses · doi:10.3390/v12030332 · Cited by 11
“ASCT for genetic defects such as thalassemia was introduced in the 90s and achieved high cure rates for those who had a suitable donor [4].”
BackgroundSynergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction.
Habibi, H., Atashi, A., Abroun, S., & Noruzinia, M. (2019) · PubMed Central · doi:10.22074/cellj.2019.5589 · Cited by 12
“HLA donors, risk of graft versus of disease (GVHD) and virus vector transmission (5), Beta-thalassemia and SCD”
BackgroundImplementation of Fuzzy-based Model for Prediction of Thalassemia Diseases
Susanto, E. R., Syarif, A., Muludi, K., Perdani, R. R. W., & Wantoro, A. (2021) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1751/1/012034 · Cited by 11
“An easily seen disorder in thalassemia sufferers is that the child looks pale so that he experiences symptoms such as anemia[13][14].”
BackgroundSchultz, K. R., Baker, K. S., Boelens, J. J., Bollard, C. M., Egeler, R. M., Cowan, M. J., Ladenstein, R. L., Lankester, A. C., Locatelli, F., Lawitschka, Á., et al. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.07.006 · Cited by 11
“The probability of survival with HLA-matched sibling transplants reported by the Pesaro group in more than 900 patients with thalassemia age <35 years is 73% [41].”
BackgroundMustafa, M., Qatawneh, M., Jazazi, M., Jarrah, O., Hazaimeh, R., Oudat, R., Tarawneh, M. K. A., & Majali, R. A. (2020) · Materia Socio Medica · doi:10.5455/msm.2020.32.277-282 · Cited by 11
“Thalassemia is found more commonly in Mediterranean, Middle Eastern and Asian countries (3).”
Acceptability of In Utero Hematopoietic Cell Transplantation for Sickle Cell Disease
Antiel, R. M., Halpern, S. D., Stevens, E. M., Vrecenak, J. D., Patterson, C. A., Tchume-Johnson, T., Smith-Whitley, K., Peranteau, W. H., Flake, A. W., & Barakat, L. P. (2017) · Medical Decision Making · doi:10.1177/0272989x17707214 · Cited by 10
A Review of Gene Therapies for Hemoglobinopathies
Jones-Wonni, B., Kelkar, A. H., & Achebe, M. (2024) · Hemoglobin · doi:10.1080/03630269.2024.2369534 · Cited by 12
“Allogeneic hematopoietic stem cell transplantation (HCT) is established as a curative option for both sickle cell disease and ß-thalassemia [11,12].”
An overview of current treatment strategies for β-thalassemia
Cappellini, M. D., Viprakasit, V., & Taher, A. T. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.918503 · Cited by 10
Emerging cellular and gene therapies for congenital anemias
Ludwig, L. S., Khajuria, R. K., & Sankaran, V. G. (2016) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31529 · Cited by 11
“However, allogeneic transplantation of HSPCs from a healthy donor (ideally a matched sibling) into a conditioned and myeloablated recipient is currently the only curative option available in a clinical setting for these disorders [Lucarelli et al., 2012].”
BackgroundHuang, K., Zhou, D., Li, Y., Xu, H., Que, L., Chen, C., Xue, H., Guo, H., Weng, W., Huang, S.-L., et al. (2018) · Pediatric Blood & Cancer · doi:10.1002/pbc.27026 · Cited by 9
Akhtar, S. O., Raza, A. A., Abdullah, Y., & Samadi, A. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003404 · Cited by 7
“Despite these treatments, many patients with thalassemia face significant health challenges, and the only potential cure is HSCT [ 29 ] .”
Andreani, M., Testi, M., Sodani, P., Troiano, M., Luzio, A. D., Testa, G., Falco, M., Poggi, E., Gaziev, J., & Piazza, A. (2017) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2017.020 · Cited by 7
Self-citationde Azevedo, J. T. C., Costa, T. C. D. M., Lima, K. C., Maciel, T. T., Palma, P. V. B., Darrigo, L. G., Grecco, C. E. S., Stracieri, A. B. P. L., Elias, J., Pieroni, F., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.774442 · Cited by 9
Aslam, H. M., Yousuf, S., Kassim, A. A., Iqbal, S. M., & Hashmi, S. K. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0193-6 · Cited by 8
“23 Clinical trial 2009 22 19 3 (severe lung injury) 8 10 aGVHD; 6 cGVHD 3 [49]”
Characterization of mesenchymal stem cells in mucolipidosis type II (I-cell disease)
Köse, S., Aerts‐Kaya, F., Kuşkonmaz, B., & Uçkan, D. (2019) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1902-20 · Cited by 9
“, 2010), lymphomas (Bhatt and Vose, 2014), anemias (Lucarelli et al., 2012), and certain metabolic disorders (Wynn, 2011).”
BackgroundBayegi, S. N., Hamidieh, A. A., Behfar, M., Bozorgmehr, M., Saghazadeh, A., Tajik, N., Delbandi, A., Zavareh, F. T., Delavari, S., Shekarabi, M., et al. (2023) · Immunology Letters · doi:10.1016/j.imlet.2023.07.008 · Cited by 6
Khandelwal, P., Ibrahimova, A., Lane, A., Grimley, M. S., Davies, S. M., & Jodele, S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025017197 · Cited by 6
“8,9 Patients with β -thalassemia are at heightened risk for transplant-related complications due, in part, to chronic iron overload from repeated transfusions.”
Ban, Q., Lee, J., Shi, Z., Lu, D., Qiao, L., Yang, P., Li, X., Cheng, H., Zhang, M., Hou, J., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101659 · Cited by 6
Kim, S., Ruminski, P., Singh, M., Staser, K. W., Ashami, K., Ritchey, J., Lim, S., DiPersio, J. F., & Choi, J. (2024) · Molecules · doi:10.3390/molecules29081801 · Cited by 6
“Allogeneic hematopoietic cell transplantation (allo-HCT) is an effective immunotherapy for patients with both malignant disorders and nonmalignant disorders, including bone marrow failure states, hemoglobinopathies, and thalassemia [1,2].”
BackgroundGene Therapies for Transfusion-Dependent β-Thalassemia
Soni, S. (2021) · Indian Pediatrics · doi:10.1007/s13312-021-2263-x · Cited by 7
Global Trends on β-Thalassemia Research Over 10 Years: A Bibliometric Analysis
Lv, A., Li, J., Chen, M., Wang, W., Xu, L., & Huang, H. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s479493 · Cited by 8
Drug safety in thalassemia: lessons from the present and directions for the future
Grech, L., Sultana, J., Borg, K., & Borg, J. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1919081 · Cited by 5
“Another problem with HSCT is that the donor is ideally an HLA-identical sibling of the patient but more that 60% of the patients lack such a suitable family donor [14].”
BackgroundIalongo, C., Mozzi, A. F., & Bernardini, S. (2017) · Journal of Medical Biochemistry · doi:10.1515/jomb-2016-0031 · Cited by 5
“Hematopoietic stem cell transplantation (HSCT) represents the only therapeutic approach to grant blood transfusion-free survival to patients affected by severe thalassemia (1).”
BackgroundTransplantation in patients with iron overload: is there a place for magnetic resonance imaging?
Mavrogeni, S. I., Kolovou, G. D., Bigalke, B., Rigopoulos, A. G., Noutsias, M., & Adamopoulos, S. N. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9670-7 · Cited by 6
“In contrast to TM, SCA patients are not depending on blood transfusions to survive, but may need them under special circumstances [1, 2].”
BackgroundKhatami, M. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.215 · Cited by 5
RetractedThe role of donor-derived veto cells in nonmyeloablative haploidentical HSCT
Or‐Geva, N., & Reisner, Y. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.89 · Cited by 5
Saeidnia, M., Fazeli, P., Farzi, A., Nezhad, M. A., Shabani-Borujeni, M., Erfani, M., Tamaddon, G., & Karimi, M. (2023) · Hemoglobin · doi:10.1080/03630269.2022.2158099 · Cited by 7
Riley, J. S., Berkowitz, C. L., Luks, V. L., Dave, A., Cyril-Olutayo, M. C., Pogoriler, J. E., Flake, A. W., Abdulmalik, O. Y., & Peranteau, W. H. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012247 · Cited by 4
Martino, F., Mauro, R. D., Paciaroni, K., Gaziev, J., Alfieri, C., Greco, L., Floris, R., Girolamo, S. D., & Girolamo, M. D. (2018) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/j.ijporl.2018.01.002 · Cited by 4
Self-citationFetal allotransplant recipients are resistant to graft-versus-host disease
Riley, J. S., McClain, L. E., Stratigis, J. D., Coons, B. E., Bose, S. K., Dave, A., White, B. M., Li, H., Loukogeorgakis, S., Fachin, C. G., et al. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.12.004 · Cited by 4
Hamidieh, A. A., Saber, T., Fayyazi, S., Jalali, A., Behfar, M., Hamdi, A., & Ghavamzadeh, A. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.07.004 · Cited by 4
Hematopoietic stem cell transplantation for people with ß-thalassaemia major
Jagannath, V. A., Fedorowicz, Z., Hajeri, A. A., & Sharma, A. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008708.pub3 · Cited by 5
A Comprehensive Gap Analysis of Risk Factors for Transfusion Dependent Thalassemia in Siblings
Shekhawat, D. S., Didel, S., Purohit, A. H. L., Rajial, T., Sharma, C., Singh, P., & Singh, K. (2024) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-024-01848-1 · Cited by 3
“…only curative option available-However, it has its own limitations, viz., need of a suitably matched donor, mortality and morbidity of the procedure as well as serious complications, including immune system-mediated disorders, endocrinopathies, and impaired pulmonary and respiratory functions [12].”
Li, J., Hua, H., Liu, X., Zhou, Z., Yuan, J., & Wang, F. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115154 · Cited by 3
Hemoglobin disorders: a look to the future
Nathan, D. G. (2013) · Blood · doi:10.1182/blood-2013-06-506154 · Cited by 3
Metadata
- Authors
- Lucarelli, G., Isgro, A., Sodani, P., & Gaziev, J.
- Affiliations
- University of Rome Tor Vergata (IT)
- Corresponding author
- Lucarelli, G.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-04-04
- Volume
- 2
- Issue
- 5
- Pages
- a011825-a011825
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3331690
- OpenAlex
- W2113456470
- Cited by
- 166
- References
- 50
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 14 · 2023: 16 · 2022: 12 · 2021: 14 · 2020: 14 · 2019: 12 · 2018: 10 · 2017: 11 · 2016: 12 · 2015: 10 · 2014: 16 · 2013: 6 · 2012: 2
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hematopoietic stem cell transplantation, thalassemia, sickle cell disease, allogeneic transplantation, risk stratification, transplant toxicity, haploidentical transplantation, myeloablative conditioning, nonmyeloablative conditioning, disease-free survival
- MeSH terms
- Adult, Anemia, Sickle Cell, Graft vs Host Disease, Humans, Thalassemia, Hematopoietic Stem Cell Transplantation, Living Donors, Myeloablative Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.